ORYZON presents new positive efficacy data on vafidemstat for treatment of aggression
MADRID, SPAIN and CAMBRIDGE MA.
• Poster presented at European College of Neuropsychopharmacology Congress
• Showcases efficacy data from the autism spectrum disorder (ASD) cohort of the REIMAGINE Phase IIa trial
• Third positive clinical outcome of vafidemstat in a human CNS disorder
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, announces new positive human efficacy data on its central nervous system (CNS) epigenetic drug vafidemstat during the 32nd European College of Neuropsychopharmacology (ECNP) Congress.